195 related articles for article (PubMed ID: 21481194)
1. Post-translational modifications regulate signalling by Ror1.
Kaucká M; Krejčí P; Plevová K; Pavlová S; Procházková J; Janovská P; Valnohová J; Kozubík A; Pospíšilová S; Bryja V
Acta Physiol (Oxf); 2011 Nov; 203(3):351-62. PubMed ID: 21481194
[TBL] [Abstract][Full Text] [Related]
2. Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL).
Uhrmacher S; Schmidt C; Erdfelder F; Poll-Wolbeck SJ; Gehrke I; Hallek M; Kreuzer KA
Leuk Res; 2011 Oct; 35(10):1360-6. PubMed ID: 21531460
[TBL] [Abstract][Full Text] [Related]
3. ROR1 expression is not a unique marker of CLL.
Barna G; Mihalik R; Timár B; Tömböl J; Csende Z; Sebestyén A; Bödör C; Csernus B; Reiniger L; Peták I; Matolcsy A
Hematol Oncol; 2011 Mar; 29(1):17-21. PubMed ID: 20597086
[TBL] [Abstract][Full Text] [Related]
4. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.
Daneshmanesh AH; Mikaelsson E; Jeddi-Tehrani M; Bayat AA; Ghods R; Ostadkarampour M; Akhondi M; Lagercrantz S; Larsson C; Osterborg A; Shokri F; Mellstedt H; Rabbani H
Int J Cancer; 2008 Sep; 123(5):1190-5. PubMed ID: 18546292
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.
Daneshmanesh AH; Hojjat-Farsangi M; Khan AS; Jeddi-Tehrani M; Akhondi MM; Bayat AA; Ghods R; Mahmoudi AR; Hadavi R; Österborg A; Shokri F; Rabbani H; Mellstedt H
Leukemia; 2012 Jun; 26(6):1348-55. PubMed ID: 22289919
[TBL] [Abstract][Full Text] [Related]
6. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.
Baskar S; Kwong KY; Hofer T; Levy JM; Kennedy MG; Lee E; Staudt LM; Wilson WH; Wiestner A; Rader C
Clin Cancer Res; 2008 Jan; 14(2):396-404. PubMed ID: 18223214
[TBL] [Abstract][Full Text] [Related]
7. Differential subcellular localization of Ror tyrosine kinase receptors in cultured astrocytes.
Paganoni S; Anderson KL; Ferreira A
Glia; 2004 May; 46(4):456-66. PubMed ID: 15095375
[TBL] [Abstract][Full Text] [Related]
8. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells.
Li P; Harris D; Liu Z; Liu J; Keating M; Estrov Z
PLoS One; 2010 Jul; 5(7):e11859. PubMed ID: 20686606
[TBL] [Abstract][Full Text] [Related]
9. Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia.
Janovska P; Poppova L; Plevova K; Plesingerova H; Behal M; Kaucka M; Ovesna P; Hlozkova M; Borsky M; Stehlikova O; Brychtova Y; Doubek M; Machalova M; Baskar S; Kozubik A; Pospisilova S; Pavlova S; Bryja V
Clin Cancer Res; 2016 Jan; 22(2):459-69. PubMed ID: 26240275
[TBL] [Abstract][Full Text] [Related]
10. The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.
Hojjat-Farsangi M; Khan AS; Daneshmanesh AH; Moshfegh A; Sandin A; Mansouri L; Palma M; Lundin J; Österborg A; Mellstedt H
PLoS One; 2013; 8(10):e78339. PubMed ID: 24205204
[TBL] [Abstract][Full Text] [Related]
11. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
12. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.
Hasan MK; Yu J; Chen L; Cui B; Widhopf Ii GF; Rassenti L; Shen Z; Briggs SP; Kipps TJ
Leukemia; 2017 Dec; 31(12):2615-2622. PubMed ID: 28465529
[TBL] [Abstract][Full Text] [Related]
13. N-Glycosylation of the human kappa opioid receptor enhances its stability but slows its trafficking along the biosynthesis pathway.
Li JG; Chen C; Liu-Chen LY
Biochemistry; 2007 Sep; 46(38):10960-70. PubMed ID: 17711303
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.
Hojjat-Farsangi M; Jeddi-Tehrani M; Daneshmanesh AH; Mozaffari F; Moshfegh A; Hansson L; Razavi SM; Sharifian RA; Rabbani H; Österborg A; Mellstedt H; Shokri F
PLoS One; 2015; 10(11):e0142310. PubMed ID: 26562161
[TBL] [Abstract][Full Text] [Related]
15. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.
Yu J; Chen L; Cui B; Widhopf GF; Shen Z; Wu R; Zhang L; Zhang S; Briggs SP; Kipps TJ
J Clin Invest; 2016 Feb; 126(2):585-98. PubMed ID: 26690702
[TBL] [Abstract][Full Text] [Related]
16. Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells.
Choudhury A; Derkow K; Daneshmanesh AH; Mikaelsson E; Kiaii S; Kokhaei P; Osterborg A; Mellstedt H
Br J Haematol; 2010 Nov; 151(4):327-35. PubMed ID: 20813009
[TBL] [Abstract][Full Text] [Related]
17. Analysis of ROR1 Protein Expression in Mice with Reconstituted Human Immune System Components.
Leung CS
J Immunol Res; 2018; 2018():2480931. PubMed ID: 29850623
[TBL] [Abstract][Full Text] [Related]
18. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a.
Fukuda T; Chen L; Endo T; Tang L; Lu D; Castro JE; Widhopf GF; Rassenti LZ; Cantwell MJ; Prussak CE; Carson DA; Kipps TJ
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3047-52. PubMed ID: 18287027
[TBL] [Abstract][Full Text] [Related]
19. Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.
Yu J; Chen L; Chen Y; Hasan MK; Ghia EM; Zhang L; Wu R; Rassenti LZ; Widhopf GF; Shen Z; Briggs SP; Kipps TJ
Leukemia; 2017 Dec; 31(12):2608-2614. PubMed ID: 28465528
[TBL] [Abstract][Full Text] [Related]
20. Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells.
Hasan MK; Rassenti L; Widhopf GF; Yu J; Kipps TJ
Leukemia; 2019 Mar; 33(3):653-661. PubMed ID: 30568170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
